Table 2 Change from baseline in lymphocyte sub-populations, EBV and CMV DNA counts, and CRP a
Median percent change in lymphocyte sub-population cell counts, cells/mm3(Q25, Q75) | |||||
|---|---|---|---|---|---|
Time point | Placebo | Tofacitinib | Tofacitinib | Tofacitinib | |
2 mg BID | 5 mg BID | 15 mg BID | |||
T (CD3+) | Week 4 | −0.39 (−14.03, 9.75) | 4.79 (−7.45, 17.57) | 6.36 (−4.05, 24.24) | 8.38 (−9.07, 42.80) |
Week 12 | 2.28 (−8.31, 11.10) | 0.10 (−17.18, 15.87) | 3.73 (−11.75, 17.54) | 0.65 (−23.86, 17.64) | |
TH (CD3+/CD4+) | Week 4 | −0.14 (−10.71, 12.20) | 5.52 (−6.73, 18.12) | 9.56 (0, 30.24) | 15.09 (−5.39, 56.12) |
Week 12 | 0.89 (−7.00, 15.95) | −0.90 (−12.29, 15.42) | 3.82 (−9.54, 17.99) | −0.82 (−22.29, 32.57) | |
TC (CD3+/CD8+) | Week 4 | −4.79 (−12.42, 15.01) | 5.13 (−13.33, 19.62) | 0.29 (−9.45, 27.35) | −0.23 (−19.05, 47.92) |
Week 12 | 3.74 (−11.43, 18.42) | −5.58 (−16.27, 11.29) | −1.48 (−12.46, 14.07) | −0.33 (−28.53, 24.61) | |
B (CD19+) | Week 4 | −6.87 (−19.05, 11.40) | 23.88 (6.60, 43.13) | 45.17 (16.28, 56.84) | 67.90 (32.64, 103.79) |
Week 12 | −0.67 (−12.93, 18.09) | 18.03 (0.94, 47.37) | 35.32 (9.66, 66.32) | 42.86 (16.74, 67.50) | |
NK (CD16+/CD56+) | Week 4 | 0 (−27.68, 37.60) | −10.94 (−28.17, 8.28) | −26.11 (−46.71, 4.35) | −40.80 (−52.50, −10.06) |
Week 12 | 13.87 (−21.43, 26.67) | −20.00 (−34.17, 3.97) | −22.76 (−51.38, −1.59) | −34.31 (−57.07, −16.57) | |
Median change in viral load, copies/500 ng total DNA (Q25, Q75) | |||||
CMV | Week 4 | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) |
Week 8 | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.90) | |
Week 12 | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) | |
EBV | Week 12 | 0 (−1.10, 0.00) | 0 (0.00, 1.25) | 0 (0.00, 0.60) | 0.70 (0.00, 2.90) |
Median percent change in CRP, % (Q25, Q75) | |||||
CRP | Week 12 | 9.42 (−52.41, 61.08) | −24.71 (−47.43, 5.49) | −36.31 (−74.62, 5.49) | −69.17 (−82.20, −34.38) |